Blocking the PD-1/PD-L1 interaction with anti–PD-L1 or PD-L1 antibody restores, could reverse the dysfunctional status of PD-1+ NK cells and restore the anti-tumor response of NK cells (49, 50). The gene discussed is PDCD1; the disease is neoplasm.